These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 30362019)

  • 1. Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.
    Ma H; Sawas A
    Curr Hematol Malig Rep; 2018 Dec; 13(6):555-569. PubMed ID: 30362019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
    Ricart AD
    Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
    Herrera AF; Molina A
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index.
    Coats S; Williams M; Kebble B; Dixit R; Tseng L; Yao NS; Tice DA; Soria JC
    Clin Cancer Res; 2019 Sep; 25(18):5441-5448. PubMed ID: 30979742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antibody-Drug Conjugate for Treating Leukemia and Lymphoma-The Present Status, Problems, and Future Development].
    Ida N; Yamauchi T
    Gan To Kagaku Ryoho; 2024 Jul; 51(7):686-690. PubMed ID: 39191681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-drug conjugate technology development for hematologic disorders.
    Bander NH; Czuczman MS; Younes A
    Clin Adv Hematol Oncol; 2012 Aug; 10(8 Suppl 10):1-16. PubMed ID: 23072775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
    Shor B; Gerber HP; Sapra P
    Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Aujla A; Aujla R; Liu D
    Biomark Res; 2019; 7():9. PubMed ID: 31011424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calicheamicin Antibody-Drug Conjugates with Improved Properties.
    Vollmar BS; Frantz C; Schutten MM; Zhong F; Del Rosario G; Go MAT; Yu SF; Leipold DD; Kamath AV; Ng C; Xu K; Dela Cruz-Chuh J; Kozak KR; Chen J; Xu Z; Wai J; Adhikari P; Erickson HK; Dragovich PS; Polson AG; Pillow TH
    Mol Cancer Ther; 2021 Jun; 20(6):1112-1120. PubMed ID: 33722856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
    Lambert JM; Morris CQ
    Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies.
    Fabbri A; Cencini E; Gozzetti A; Schiattone L; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(7):886-895. PubMed ID: 27592544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
    Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
    Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.
    Li H; Han TH; Hunder NN; Jang G; Zhao B
    J Clin Pharmacol; 2017 Sep; 57(9):1148-1158. PubMed ID: 28513851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour-targeted chemotherapy with immunoconjugates of calicheamicin.
    Damle NK
    Expert Opin Biol Ther; 2004 Sep; 4(9):1445-52. PubMed ID: 15335312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.
    Mehta A; Forero-Torres A
    Curr Oncol Rep; 2015 Sep; 17(9):41. PubMed ID: 26194424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antibody-drug conjugates: a new therapeutic class?].
    Chofflon I; Dietrich PY; Thang NN
    Rev Med Suisse; 2013 May; 9(387):1080-2, 1084-6. PubMed ID: 23757915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies.
    Fanale MA; Forero-Torres A; Rosenblatt JD; Advani RH; Franklin AR; Kennedy DA; Han TH; Sievers EL; Bartlett NL
    Clin Cancer Res; 2012 Jan; 18(1):248-55. PubMed ID: 22080439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Characterization of Catabolic Pathways and Metabolism of ABBV-011, a Novel Calicheamicin-Based SEZ6-Targeting Antibody-Drug Conjugate.
    Ladror D; Gu C; Tong V; Schammel A; Gavrilyuk J; Haight A; Sarvaiya H
    Drug Metab Dispos; 2024 Jan; 52(2):135-142. PubMed ID: 38050039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates: present and future.
    Beck A; Reichert JM
    MAbs; 2014; 6(1):15-7. PubMed ID: 24423577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.